EDAP has developed an innovative HIFU treatment device for prostate and other cancers, which it was already selling. The offering is boosted by an exclusive distribution deal with the maker of a complementary device and the upcoming Category 1 CPT reimbursement code. The shares are a steal unless the COVID-19 pandemic worsens, as the company’s […]
Entries Tagged as 'EDAP'
June 7th, 2020 · Comments Off on EDAP Shares Are Still A Steal, But The Pandemic Could Be A Wrench
May 5th, 2020 · Comments Off on (Exclusive) The Selloff In EDAP Looks Overdone
EDAP, developer of promising medical devices for HIFU and ESWL treatments, has been buffeted by hospitals concentrating on treating Covid-19 patients. However, this looks like postponement to us, with little long-term damage to the company’s perspectives, which remain bright. We therefore see the 50%+ correction in the share price as an opportunity. Source: (Exclusive) The […]
October 7th, 2019 · Comments Off on EDAP Is At An Inflection Point
The company is in the first inning with its HIFU treatment of prostate cancer, enjoying near triple-rate growth in Q2. Its other business is more steady, but also had a good quarter. Given the growth, the large margin expansion and profitability, and the additional HIFU treatment opportunities further away in time we think the shares […]